Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AMRX Stock Forecast 2026-2027
$16.24
Current Price
$5.17B
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AMRX Price Targets
+17.0%
To High Target of $19.00
+4.7%
To Median Target of $17.00
-1.5%
To Low Target of $16.00
AMRX Price Momentum
+10.6%
1 Week Change
+36.1%
1 Month Change
+100.2%
1 Year Change
+28.9%
Year-to-Date Change
-2.2%
From 52W High of $16.61
+111.9%
From 52W Low of $7.67
📊 TOP ANALYST CALLS
Did AMRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Amneal Pharmaceuticals is one of their latest high-conviction picks.
Latest AMRX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, AMRX has a bullish consensus with a median price target of $17.00 (ranging from $16.00 to $19.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $16.24, the median forecast implies a 4.7% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Glen Santangelo at Barclays, suggesting a 1.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AMRX Analyst Ratings
4
Buy
0
Hold
0
Sell
AMRX Price Target Range
Low
$16.00
Average
$17.00
High
$19.00
Current: $16.24
Latest AMRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AMRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 20, 2026 | Barclays | Glen Santangelo | Overweight | Maintains | $16.00 |
| Apr 17, 2026 | UBS | Buy | Initiates | $N/A | |
| Mar 2, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Dec 9, 2025 | Barclays | Overweight | Initiates | $N/A | |
| Oct 31, 2025 | Piper Sandler | Overweight | Reiterates | $N/A | |
| Sep 16, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Mar 3, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Feb 24, 2025 | JP Morgan | Overweight | Upgrade | $N/A | |
| Nov 11, 2024 | Piper Sandler | Overweight | Maintains | $N/A | |
| Oct 2, 2024 | Truist Securities | Buy | Maintains | $N/A | |
| Sep 6, 2024 | JP Morgan | Neutral | Upgrade | $N/A | |
| Aug 13, 2024 | Barclays | Overweight | Maintains | $N/A | |
| Aug 12, 2024 | Truist Securities | Buy | Maintains | $N/A | |
| May 6, 2024 | Goldman Sachs | Buy | Maintains | $N/A | |
| May 6, 2024 | Truist Securities | Buy | Reiterates | $N/A | |
| Mar 21, 2024 | Piper Sandler | Overweight | Maintains | $N/A | |
| Mar 4, 2024 | Goldman Sachs | Buy | Maintains | $N/A | |
| Jan 29, 2024 | Barclays | Overweight | Maintains | $N/A | |
| Nov 8, 2023 | Truist Securities | Buy | Maintains | $N/A | |
| Sep 6, 2023 | Truist Securities | Buy | Reiterates | $N/A |
Amneal Pharmaceuticals Inc. (AMRX) Competitors
The following stocks are similar to Amneal Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Amneal Pharmaceuticals Inc. (AMRX) Financial Data
Amneal Pharmaceuticals Inc. has a market capitalization of $5.17B with a P/E ratio of 43.8x. The company generates $3.05B in trailing twelve-month revenue with a 4.0% profit margin.
Revenue growth is +3.9% quarter-over-quarter, while maintaining an operating margin of +19.6% and return on equity of -101.0%.
Valuation Metrics
Market Cap
$5.17B
Enterprise Value
$7.75B
P/E Ratio
43.8x
PEG Ratio
0.1x
Price/Sales
1.7x
Growth & Margins
Revenue Growth (YoY)
+3.9%
Gross Margin
+44.3%
Operating Margin
+19.6%
Net Margin
+4.0%
EPS Growth
+410.5%
Financial Health
Cash/Price Ratio
+3.9%
Current Ratio
2.5x
Debt/Equity
6,750.8x
ROE
-101.0%
ROA
+8.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Amneal Pharmaceuticals Inc. (AMRX) Business Model
About Amneal Pharmaceuticals Inc.
What They Do
Develops and distributes essential pharmaceuticals.
Business Model
The company operates three segments: Affordable Medicines, Specialty, and AvKARE, generating revenue through the production and sale of generic and branded medications, as well as supplying pharmaceuticals to government agencies. The Affordable Medicines segment focuses on a wide range of generic drugs, while the Specialty segment offers proprietary treatments for specific conditions.
Additional Information
Amneal Pharmaceuticals operates in the U.S., India, and Ireland and emphasizes innovation and affordability in its offerings. Founded in 2002 and headquartered in Bridgewater, New Jersey, the company plays a significant role in the generics, specialty, and institutional pharmaceuticals markets.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
8,300
CEO
Mr. Chirag K. Patel
Country
United States
IPO Year
2018
Website
www.amneal.comAmneal Pharmaceuticals Inc. (AMRX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
Here is how Amarin (AMRN) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Jun 12, 2026
By Zacks Equity Research
Tale of the Tape
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Jun 11, 2026
By Zacks Equity Research
52 Week High
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.
Jun 09, 2026
By Kanishka Das
Analyst Blog Plus
Latest News
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
5 days ago
Quick Summary
Amneal supports Dispensary of Hope's "Hope Alliance" campaign, aimed at improving access to essential medications for low-income and uninsured patients nationwide.
Why It Matters
Amneal's support for essential medicines enhances its corporate reputation and aligns with social responsibility trends, potentially attracting socially conscious investors and improving market positioning.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Amneal (AMRX) has reached a 52-week high. Investors are encouraged to examine the company's fundamentals for potential future gains.
Why It Matters
Amneal's 52-week high signals strong performance, but analyzing its fundamentals will reveal potential for future growth and risk factors, influencing investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Amneal Pharmaceuticals (NASDAQ: AMRX) is entering a growth phase, fueled by its generics portfolio, expanded biosimilars platform, and new specialty product launches.
Why It Matters
Amneal's projected growth phase, fueled by generics, biosimilars, and specialty products, signals potential revenue increases, impacting stock performance positively for investors.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Amneal Pharmaceuticals (AMRX) presented at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026, highlighting key developments and insights relevant to investors.
Why It Matters
Amneal Pharmaceuticals' presentation at a major healthcare conference signals potential insights into its future strategies and performance, impacting investor confidence and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Zacks Premium offers Style Scores to help value, growth, and momentum investors identify strong stocks more easily.
Why It Matters
Zacks Style Scores can enhance stock selection across investment strategies, potentially leading to better returns and informed decision-making for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
What's Driving Amneal's 2026 Growth Outlook?
6 days ago
Quick Summary
AMRX projects higher profits for 2026, supported by a consistent launch schedule and growth in complex generics, injectables, and specialty brands.
Why It Matters
AMRX's positive 2026 outlook indicates potential revenue growth and profitability, suggesting a favorable investment climate and enhanced shareholder value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About AMRX Stock
What is Amneal Pharmaceuticals Inc.'s (AMRX) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Amneal Pharmaceuticals Inc. (AMRX) has a median price target of $17.00. The highest price target is $19.00 and the lowest is $16.00.
Is AMRX stock a good investment in 2026?
According to current analyst ratings, AMRX has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $16.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AMRX stock?
Wall Street analysts predict AMRX stock could reach $17.00 in the next 12 months. This represents a 4.7% increase from the current price of $16.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Amneal Pharmaceuticals Inc.'s business model?
The company operates three segments: Affordable Medicines, Specialty, and AvKARE, generating revenue through the production and sale of generic and branded medications, as well as supplying pharmaceuticals to government agencies. The Affordable Medicines segment focuses on a wide range of generic drugs, while the Specialty segment offers proprietary treatments for specific conditions.
What is the highest forecasted price for AMRX Amneal Pharmaceuticals Inc.?
The highest price target for AMRX is $19.00 from at , which represents a 17.0% increase from the current price of $16.24.
What is the lowest forecasted price for AMRX Amneal Pharmaceuticals Inc.?
The lowest price target for AMRX is $16.00 from Glen Santangelo at Barclays, which represents a -1.5% decrease from the current price of $16.24.
What is the overall AMRX consensus from analysts for Amneal Pharmaceuticals Inc.?
The overall analyst consensus for AMRX is bullish. Out of 2 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are AMRX stock price projections?
Stock price projections, including those for Amneal Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 2:07 AM UTC